ArticlePulmonary medicine2011
Potential role of the inflammasome-derived inflammatory cytokines in pulmonary fibrosis.
Article in Pulmonary medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 36 citations in OpenAlex.
- NLRP3 inflammasome: structure, mechanism, drug-induced organ toxicity, therapeutic strategies, and future perspectives.RSC medicinal chemistry · 2025Review
- Article
- Advances in the Use ofAntioxidants (Basel, Switzerland) · 2023Review
- Molecular recognition between membrane epitopes and nearly free surface silanols explains silica membranolytic activity.Colloids and surfaces. B, Biointerfaces · 2022Article
- Associations of SMAD4 rs10502913 and NLRP3 rs1539019 Polymorphisms with Risk of Coal Workers' Pneumoconiosis Susceptibility in Chinese Han Population.Pharmacogenomics and personalized medicine · 2022Article
- The Crucial Role of NLRP3 Inflammasome in Viral Infection-Associated Fibrosing Interstitial Lung Diseases.International journal of molecular sciences · 2021Review
- New Insights into Pathomechanisms and Treatment Possibilities for Lung Silicosis.International journal of molecular sciences · 2021Review
- Role of CXCL16 in BLM-induced epithelial-mesenchymal transition in human A549 cells.Respiratory research · 2021Article
- Conditioned medium from asbestos-exposed fibroblasts affects proliferation and invasion of lung cancer cell lines.PloS one · 2019Article
- Inhibition of the TGF-β/Smads signaling pathway attenuates pulmonary fibrosis and induces anti-proliferative effect on synovial fibroblasts in rheumatoid arthritis.International journal of clinical and experimental pathology · 2019Article
- Comparison of the toxicity of sintered and unsintered indium-tin oxide particles in murine macrophage and epidermal cells.Toxicology and applied pharmacology · 2017Article
- Local administration of Trolox, a vitamin E analog, reduced tendon adhesion in a chicken model of flexor digitorum profundus tendon injury.Journal of orthopaedic translation · 2017Article
- Evaluating the mechanistic evidence and key data gaps in assessing the potential carcinogenicity of carbon nanotubes and nanofibers in humans.Critical reviews in toxicology · 2017Review
- The NLRP3 inflammasome in pathogenic particle and fibre-associated lung inflammation and diseases.Particle and fibre toxicology · 2016Review
- Sintered indium-tin oxide particles induce pro-inflammatory responses in vitro, in part through inflammasome activation.PloS one · 2015Article
- Nonmicrobial-mediated inflammatory airway diseases--an update.Journal of physiology and biochemistry · 2014Review
- Role of lysosomes in silica-induced inflammasome activation and inflammation in absence of MARCO.Journal of immunology research · 2014Article
- Autoimmunity and asbestos exposure.Autoimmune diseases · 2014Review
- Regulatory effect of caffeic acid phenethyl ester on type I collagen and interferon-gamma in bleomycin-induced pulmonary fibrosis in rat.Research in pharmaceutical sciences · 2013Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary fibrosis is a progressive, disabling disease with mortality rates that appear to be increasing in the western population, including the USA. There are over 140 known causes of pulmonary fibrosis as well as many unknown causes. Treatment options for this disease are limited due to poor understanding of the molecular mechanisms of the disease progression. However, recent progress in inflammasome research has greatly contributed to our understanding of its role in inflammation and fibrosis development. The inflammasome is a multiprotein complex that is an important component of both the innate and adaptive immune systems. Activation of proinflammatory cytokines following inflammasome assembly, such as IL-1β and IL-18, has been associated with development of PF. In addition, components of the inflammasome complex itself, such as the adaptor protein ASC have been associated with PF development. Recent evidence suggesting that the fibrotic process can be reversed via blockade of pathways associated with inflammasome activity may provide hope for future drug strategies. In this paper we will give an introduction to pulmonary fibrosis and its known causes. In addition, we will discuss the importance of the inflammasome in the development of pulmonary fibrosis as well as discuss potential future treatment options.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.